Sei Investments CO Blueprint Medicines Corp Transaction History

Sei Investments CO

$74.7 Billion
Q3 2024

A detailed history of Sei Investments CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Sei Investments CO holds 63,973 shares of BPMC stock, worth $5.67 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

63,973

Previous 52,986 20.74%

Holding current value

$5.67 Million

Previous $5.71 Million 3.57%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$84.1 - $120.5 $924,006 - $1.32 Million	10,987 Added 20.74%	63,973 $5.91 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $602,478 - $769,400	7,073 Added 15.41%	52,986 $5.71 Million
Q1 2024 May 07, 2024	BUY	$73.17 - $99.79 $900,795 - $1.23 Million	12,311 Added 36.64%	45,913 $4.36 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $241,867 - $510,805	5,502 Added 19.58%	33,602 $3.1 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $445,643 - $627,132	9,502 Added 51.09%	28,100 $1.41 Million
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $186,228 - $292,890	4,413 Added 31.11%	18,598 $1.18 Million
Q1 2023 May 12, 2023	BUY	$37.97 - $50.0 $103,354 - $136,100	2,722 Added 23.75%	14,185 $638,000
Q4 2022 Feb 10, 2023	BUY	$41.06 - $66.48 $99,036 - $160,349	2,412 Added 26.65%	11,463 $502,000
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $50,479 - $78,554	-1,011 Reduced 10.05%	9,051 $596,000
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $590,161 - $915,317	-13,048 Reduced 56.46%	10,062 $508,000
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $643,573 - $1.31 Million	-11,896 Reduced 33.98%	23,110 $1.48 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $35,532 - $43,728	-377 Reduced 1.07%	35,006 $3.76 Million
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $146,006 - $197,374	-1,803 Reduced 4.85%	35,383 $3.64 Million
Q2 2021 Aug 06, 2021	SELL	$82.78 - $101.0 $3.03 Million - $3.7 Million	-36,587 Reduced 49.59%	37,186 $3.27 Million
Q1 2021 May 12, 2021	BUY	$90.71 - $108.28 $1.37 Million - $1.63 Million	15,073 Added 25.68%	73,773 $7.33 Million
Q4 2020 Feb 08, 2021	SELL	$92.08 - $124.48 $6.02 Million - $8.14 Million	-65,366 Reduced 52.69%	58,700 $6.58 Million
Q3 2020 Nov 06, 2020	BUY	$66.45 - $92.7 $556,452 - $776,269	8,374 Added 7.24%	124,066 $11.5 Million
Q2 2020 Aug 17, 2020	BUY	$57.09 - $79.27 $3.72 Million - $5.17 Million	65,199 Added 129.12%	115,692 $9.03 Million
Q2 2020 Aug 11, 2020	SELL	$57.09 - $79.27 $380,847 - $528,810	-6,671 Reduced 11.67%	50,493 $4.05 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $345,814 - $590,997	7,188 Added 14.38%	57,164 $3.34 Million
Q4 2019 Feb 06, 2020	BUY	$66.73 - $82.59 $171,362 - $212,091	2,568 Added 5.42%	49,976 $4 Million
Q3 2019 Nov 12, 2019	BUY	$72.9 - $101.41 $1.66 Million - $2.31 Million	22,821 Added 92.82%	47,408 $3.48 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $400,866 - $533,107	-5,451 Reduced 18.15%	24,587 $2.32 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $647,369 - $1.15 Million	-13,293 Reduced 30.68%	30,038 $2.4 Million
Q4 2018 Feb 13, 2019	SELL	$45.57 - $74.26 $410 - $668	-9 Reduced 0.02%	43,331 $3.37 Million
Q3 2018 Nov 08, 2018	BUY	$58.91 - $78.32 $107,982 - $143,560	1,833 Added 4.42%	43,340 $3.38 Million
Q2 2018 Aug 03, 2018	BUY	$60.96 - $101.18 $636,239 - $1.06 Million	10,437 Added 33.59%	41,507 $2.64 Million
Q1 2018 May 11, 2018	SELL	$73.28 - $102.95 $3.18 Million - $4.47 Million	-43,438 Reduced 58.3%	31,070 $2.85 Million
Q4 2017 Feb 08, 2018	BUY	$62.91 - $88.32 $959,817 - $1.35 Million	15,257 Added 25.75%	74,508 $5.62 Million
Q3 2017 Nov 06, 2017	BUY	$42.37 - $69.67 $2.51 Million - $4.13 Million	59,251	59,251 $4.13 Million

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account

Sei Investments CO Blueprint Medicines Corp Transaction History